argenx Announces Positive Phase 3 ALKIVIA Topline for VYVGART Hytrulo in Autoimmune Myositis
Aug 17, 2026, 1:03 AM EDT3 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strong topline efficacy in a historically untapped IMNM cohort, durable effect, and favorable safety profile can trigger a positive re-rating. Significance is higher in IMNM than DM due to statistical significance; overall read-through supports upside in ARGX’s FcRn portfolio and potential pipeline expansion.
AI summary
What happened, with direct paths to the underlying reporting
argenx announced positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in autoimmune myositis (IMNM+DM), meeting the primary endpoint with a 15.4-point mean TIS improvement at Week 52 (p=0.0011). Improvements appeared early (Week 4) and were sustained over a year, with the IMNM subgroup achieving significance (p=0.0048). A conference call is planned Aug 17; potential read-through could support near-term upside for ARGX and its FcRn strategy.
ALKIVIA Phase 3 topline: primary endpoint met; p=0.0011 for mean TIS at Week 52.
Combined IMNM+DM shows 15.4-point TIS improvement (47.95 vs 32.56).
IMNM subgroup met endpoint (p=0.0048); DM improvement similar but not statistically significant.
VYVGART Hytrulo well‑tolerated; early and durable benefit through year; safety aligns with prior data.
Conference call on Aug 17 2:30 PM CET / 8:30 AM ET to discuss results.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
argenx announced it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in Sjögren’s disease after an IDMC recommendation to stop for futility at interim analysi…
argenx announced positive Phase 2 results for FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The primary endpoint—change in villus height-to-crypt depth a…
argenx is acquiring Forte Biosciences for $77 per share in cash, valuing Forte at about $2.2 billion. Forte's FB102 anti-CD122 antibody has Phase 1b signals in vitiligo and celiac…
Argenx updated its Phase 3 myositis plan, separating IMNM and DM analyses and dropping PM. HC Wainwright remains bullish on Vyvgart, citing IMNM's potential to exceed $1B in sales…